A potential breakthrough in the fight against sepsis – a leading cause of death globally – has emerged from research at Adelaide University. Scientists have discovered that restoring levels of a naturally occurring protein, corticosteroid-binding globulin (CBG), dramatically improved survival rates in animal models of septic shock. This finding is particularly significant as it represents the first potentially novel, naturally-derived anti-inflammatory agent identified in over 70 years, addressing a critical gap in sepsis treatment.
- Sepsis Survival Boost: Restoring CBG levels led to a 70% reduction in mortality in animal models with septic shock.
- Novel Anti-Inflammatory: CBG appears to trigger an anti-inflammatory response through a previously unknown mechanism, offering a new therapeutic avenue.
- Clinical Trials Imminent: Researchers are preparing for first-in-human clinical trials, with potential applications extending beyond sepsis to conditions like severe burns.
Sepsis arises when the body’s response to an infection spirals out of control, causing widespread inflammation and organ damage. The escalating incidence of sepsis is a growing concern, fueled by factors like an aging population, increasing rates of invasive procedures (surgery, implants), and the rise in immunosuppressive therapies used to treat autoimmune diseases and prevent organ rejection. Current treatments for septic shock – the most severe form of sepsis – remain limited and often ineffective, leaving a desperate need for new interventions. The lack of progress in developing new therapies for sepsis in recent decades underscores the urgency of this discovery.
The Adelaide team’s research, spanning 13 years, revealed a strong correlation between CBG deficiency and increased mortality in intensive care patients with septic shock. CBG, normally produced by the liver, transports the stress hormone cortisol. However, the protective effect observed in the study appears independent of cortisol, suggesting CBG has a direct anti-inflammatory role. This is a crucial distinction, as manipulating cortisol levels can have significant side effects. The study demonstrated marked protection against sepsis progression, reducing both dangerously low blood pressure and organ damage in the animal models.
The Forward Look
The transition to human clinical trials is the immediate next step. AusHealth is already producing CBG for these trials, suggesting a streamlined path towards testing safety and efficacy in patients. However, several key questions remain. The trials will need to determine the optimal dosage and delivery method for CBG. Researchers will also be closely monitoring for any adverse effects, although initial indications suggest minimal toxicity. Beyond sepsis, the team is exploring CBG’s potential in treating severe burn injuries and other conditions characterized by CBG depletion, broadening the potential impact of this discovery. Success in these trials could not only revolutionize sepsis treatment but also open up new avenues for managing inflammatory responses in a wide range of critical illnesses. The scientific community will be watching closely for the results, as a positive outcome could represent a paradigm shift in how we approach life-threatening inflammatory conditions.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
